Calculus VCT plc
Half
Yearly Report for the six months ended 30 September
2024
INVESTMENT OBJECTIVE
The Company's principal objectives
for investors are to:
● invest in
a portfolio of Venture Capital Investments that will provide
investment returns that are sufficient to allow the Company to
maximise dividends and capital growth over the medium to long
term;
● generate
sufficient returns from a portfolio of Venture Capital Investments
that will provide attractive long-term returns within a tax
efficient vehicle;
● review and
pay the appropriate level of dividends annually taking account of
investment returns achieved and future prospects; and
● maintain
VCT status to enable qualifying investors to retain their income
tax relief of up to 30 per cent. on the initial investment and
receive tax-free dividends and capital growth.
FINANCIAL OVERVIEW
Financial Highlights
|
6 months to
30-Sep-24
|
|
13 months to
31-Mar-24
|
|
6 months to
31-Aug-23
|
|
pence
|
|
pence
|
|
pence
|
Opening net asset value
|
61.58
|
|
65.53
|
|
65.63
|
Capital loss
|
(1.74)
|
|
(1.26)
|
|
(1.04)
|
Revenue return
|
0.22
|
|
0.37
|
|
0.11
|
Total return1
|
(1.52)
|
|
(0.89)
|
|
(0.93)
|
Dividends paid
|
(2.77)
|
|
(2.95)
|
|
(2.95)
|
Impact of share capital
movements
|
(0.09)
|
|
(0.11)
|
|
(0.20)
|
Closing net asset value
|
57.20
|
|
61.58
|
|
61.55
|
Total Shareholder value
|
Ordinary
shares (pence per share)
|
Total dividends paid to 30 September
20242
|
26.65
|
Net asset value on 30 September
2024
|
57.20
|
Total shareholder value to 30 September 2024
|
83.85
|
2 total dividends paid include cumulative dividends paid since
2017
£41.29m
Total Net Assets as at 30 September
2024
|
57.20p
NAV per share as at 30 September
2024
|
£1.3m
Total cost of new and follow-on
investments in the six months to 30 September 2024
|
1.00X
5-year total return
|
£5.8m
Funds raised in the six months to 30
September 2024
|
£2.0m
Dividends paid out in the six months
to 30 September 2024
|
£0.5m
Shares bought back in the six months
to 30 September 2024
|
37 Portfolio companies at period-end
|
Historical Total Return
Financial period-end
|
NAV
at period-end
|
Cumulative dividends received (p)*
|
Total return (p)**
|
30 September 2024
|
57.20
|
-
|
57.20
|
31 August 2023
|
61.55
|
2.77
|
59.97
|
31 August 2022
|
64.61
|
5.72
|
62.92
|
31 August 2021
|
64.01
|
8.78
|
65.98
|
31 August 2020
|
64.27
|
11.80
|
69.00
|
31 August 2019
|
72.20
|
15.00
|
72.20
|
* Cumulative dividends received includes all dividends received
since the relevant Financial period-end to date
** Total NAV return is equal to the sum of NAV at 30 September
2024 and cumulative dividends received
CHAIRMAN'S UPDATE
I am pleased to present your
Company's results for the 6 months to 30 September 2024.
Performance summary
The Company has maintained a positive
total return over a five-year period across the portfolio.
The NAV at the period end was 57.20 pence per
share, which, after paying the 2.77 pence dividend in August 2024,
represents a small decrease of 3% since the year
end.
The largest positive movements in the
qualifying portfolio derived from the de-listing of C4X Discovery
Holdings plc (now C4X Discovery Holdings Limited), an uplift in Blu
Wireless Technology Limited following the conversion of a loan note
in May 2024 and an uplift in Scancell plc, one of the Company's
AIM-listed holdings. These combine to make a £0.6m uplift in the
Company's NAV.
In October 2024, Chancellor Rachel
Reeves announced a number of changes to how capital gains and
inheritance taxes are charged. In a high tax landscape, the VCT
product range remains a stable and reliable source of tax relief.
The new Chancellor used the Autumn Statement as an opportunity to
identify the critical role VCT schemes play in creating a positive
environment for UK entrepreneurship. Offering tax free capital
growth, 30% income tax relief on the value of the investment and
tax-free dividend income; the Calculus VCT remains a credible and
dependable tax efficient investment product for UK
investors.
Additionally, we are pleased to
report positive developments in our dividend policy, reflecting our
continued confidence of our portfolio and our commitment to
delivering value to our shareholders. Following careful
consideration, we are increasing the annual dividend yield from
4.5% to 5%, marking a significant step in enhancing shareholder
returns. Furthermore, I am delighted to introduce an interim
dividend, which will provide shareholders with more frequent income
distributions and align with our goal of steady and predictable
returns. These changes underscore our confidence in the outlook for
the business and our ability to generate sustainable growth. Please
refer to the "New Dividend Target" below for further information
regarding the Company's dividend policy.
Open Energy Market ('OEM') has
continued to build on what was a strong 2023 where revenues for the
year ended 31 Jan 2024 increased by 34%. As a result, OEM's
performance contributed £0.1m to the Company's NAV. This has been
underpinned by increasing successful traction across both the
energy intensive industry (EII) sector and increasing exposure to
and presence in the lucrative European market through existing
blue-chip multinational customers. OEM's senior management team are
in the advanced stages of finalising a two-year strategic and
operational plan, underpinned by the appointment of a new head of
finance and head of financial planning and analysis, as they target
an exit event in early 2027.
Riff Raff Entertainment Limited
('Riff Raff') has developed strongly since Calculus' first
investment in June 2022 and increased the NAV by a further £0.2m
having recently signed a two-year 'First Look' TV deal with Newen.
In August 2024, the true-crime thriller film, The Order, premiered at the Venice
Film Festival. It is set to be released in the US in December 2024.
Black Rabbit, a
major eight-part drama series, has finished production for
Netflix with Jude Law and Jason Bateman (Ozark) starring and
is in post-production.
In September 2024, eConsult was sold
to Huma Therapeutics Limited in a share-for-share deal. Huma
Therapeutics is a UK based company offering a remote patient
monitoring platform which advances connected care for patients and
accelerates research and therapies. Although Huma Therapeutics
is a large, well-funded company that recently raised $80m from
investors including AstraZeneca, the share-for-share exchange
resulted in a fall of £0.5m of the Company's NAV.
The ideas and generation market has
been challenging, leading to a large number of cost-cutting drives
within the industry. Wazoku Limited was required to cut costs
significantly throughout the year, which in turn, hit its ability
to drive strong sales. This is reflected in the valuation of the
company, resulting in a £0.5m decrease in the Company's
NAV.
In the 6-month period following the
year-end, WheelRight was acquired by Snider, a US strategic
investor and tyre trucking company. Whilst WheelRight's technology
is potentially groundbreaking, it has struggled to commercialise it
to a level which made the company self-sustaining. In May 2024,
with the company close to exhausting its cash runway, the Snider
CEO made an offer for the company in a personal capacity and
through an acquisition vehicle wholly owned by him in the amount of
£0.01 per share and which, in the absence of any other tangible
options, was agreed by all of the company's main shareholders
including Calculus. Calculus insisted on a structure that would see
its £1.6m outstanding loan notes and accrued interest paid out in
full over an extended period and which was also agreed with the
Snider CEO in a personal capacity. This saw the loan notes assigned
to the Snider CEO's corporate acquisition entity in return for
which Calculus received £400k upon completion and a promissory note
for the residual ca. £1.45 million obligating full repayment in two
tranches within 4 years.
As mentioned above, the Company also
converted £300k of Blu Wireless Technology Limited loan stock.
Following this, in June 2024, external and internal investors led a
£5m equity round into Blu Wireless Technology, with Westermo, an
industrial communications provider focused on the rail industry,
acting as lead strategic investor. As part of the round,
significant convertible loan notes were converted into equity,
resolving a key issue as these would have substantially matured
otherwise on 31 December 2024. The company is continuing to make
substantial progress in both the rail defence sectors.
In the period to 30 September 2024,
four follow-on investments were made on behalf of the qualifying
portfolio and one new investment was made:
New
investment
Date
of Investment
|
Name
of Investment
|
Location
|
Sector
|
Amount of
Investment
|
May
2024
|
Engaging Works Holding
Limited
|
United Kingdom
|
Technology
|
£666,471
|
Follow-on Investments
Date
of Investment
|
Name
of Investment
|
Location
|
Sector
|
Amount of
Investment
|
May
2024
|
Blu Wireless Technology
Limited
|
United Kingdom
|
Technology
|
£32,603
(Conversion of loan note)
|
July
2024
|
Invizius Limited
|
United Kingdom
|
Healthcare
|
£111,000
|
August 2024
|
Brouhaha Entertainment
Limited
|
United Kingdom
|
Entertainment
|
£250,000
|
August 2024
|
Optalitix Limited
|
United Kingdom
|
Technology
|
£281,894
|
We believe the portfolio is well
positioned to continue to provide long term growth to shareholders
and that our Investment Manager is similarly positioned to exploit
these opportunities.
Buybacks
During the period, the Company
bought back and cancelled 833,854 Ordinary shares. The Company
continues to review opportunities to carry out share buybacks at a
discount of no greater than 5% to NAV.
Since the period end, the Company
has bought back and cancelled a further 517,241 shares.
Dividends
As mentioned above, a dividend was
paid on 29 August 2024 of 2.77 pence per eligible Ordinary share.
It is expected that the next dividend will be paid in March 2025 as
announced below
New
Dividend Target
As mentioned in the Chairman's
Statement, the Company is targeting a regular dividend yield in
each financial year of 5% of the Net Asset Value per share at the
start of that financial year. The Company is due to pay this
dividend in two instalments; an interim dividend of 2% of the NAV,
which is due to be paid in March 2025 and a final dividend of 3% of
the NAV, which is due to be paid in October 2025.
The board are pleased to declare an
interim dividend of 1.14p per share which will be paid to
shareholders on 26 March 2025. Shareholders on the register as at
28 February 2025 will be eligible for the dividend.
Board composition
The board consist of four Directors,
three of which are independent from the Manager.
Ordinary share issue
The offer for subscription for
Ordinary Shares that opened on 22 September 2023 and closed on 29
August 2024 received aggregate subscriptions from the issue of
Ordinary shares of £7.9 million. On 14 October 2024 a new
prospectus was launched for a further offer for subscription for
Ordinary Shares, with the shares to be issued in the 2024/25 and
2025/26 tax years.
Developments since the period end
Raindog is an independent production
company co-founded by Academy Award® winning actor Colin Firth
and former music executive Ged Doherty. Since the period end, the
Company has made a follow-on investment of £450,000 in Raindog
Films Limited to support continued development in a number of
ongoing and new productions.
Jan Ward
Chairman
5 December 2024
INTERIM MANAGEMENT REPORT
Venture Capital Investments
Portfolio developments
Calculus Capital Limited manages the
Company's portfolio of venture capital investments. In general,
Calculus Capital prefers investments to be of a sufficient size to
enable them to play an influential role in helping the investee
companies develop. Investments by the Company are primarily in
equity but may also be by way of loan stock and/or preference
shares which provide income to assist in paying dividends and
provide a measure of risk mitigation.
As at 30 September 2024, the
portfolio had 37 Qualifying Investments. An update on some of the
portfolio's top investments has been provided below.
Home Team Content Limited ("Home Team")
Home Team Content is a UK-based film
and television production company founded in 2021 by experienced
and award-winning producers Dominic Buchanan and Bennett McGhee.
The company focuses on working with filmmakers of colour and women
filmmakers of any ethnicity. Home Team signed a 'first look' deal
with Universal International Studios (UIS) in 2022 covering
television productions which provides a contribution to company
overheads as well as funding development on projects picked up by
UIS. In June 2024, UIS confirmed its option to extend for a
third year on the 'First Look' deal. The company currently has
several TV and film projects in paid development with UIS, Netflix,
BBC, and Film4.
Optalitix Limited
Optalitix offers a low-code SaaS
product to insurers and financial institutions which allows
business processes based on Excel to be transformed into robust
online systems. Optalitix has performed well during the last
year with recurring revenue as at September 2024 up 46% year on
year. The pipeline for the last quarter of the year continues
to look strong, as the company is clearly achieving a strong
product-market fit in the specialty insurance underwriting
market.
Fiscaltec Group Limited ("Fiscaltec")
Fiscaltec's proprietary solution
analyses an organisation's financial transactions and supplier
contacts, providing an independent overview of the effectiveness of
the processes and controls encompassing spend. The company has
continued to perform well during 2024, enjoying particular success
upselling additional solutions to its existing list of very
committed clients. Although the economic environment of the last
year has meant that potential new customers have been cautious when
making buying decisions, Fiscaltec is focusing its efforts on the
new client pipeline in order to increase the rate of "new logo"
wins and accelerate its growth further.
Brouhaha Entertainment Limited ("Brouhaha")
Brouhaha, based in London and
Sidney, is a film and television production company founded by
Academy Award® nominated producer Gaby Tana and experienced
industry professionals Troy Lum and Andrew Mason. After the
phenomenal success of the TV Series Boy Swallows Universe on Netflix which
outperformed all expected metrics, Brouhaha is working on two other
TV projects with Netflix - Lola
in the Mirror and Love
& Virtue.
Oxford BioTherapeutics Limited ("OBT")
OBT is a clinical stage oncology
company, it's pipeline of novel immunotherapies is balanced between
internal and externally partnered programs with big pharma
companies such as Boehringer Ingelheim. In February 2024 AbbVie
(NYSE:ABBV) completed its acquisition of Immunogen, previously a
partner of OBT. Following the acquisition AbbVie took the decision
to end Immunogen's extensive, and successful, partnership with OBT.
Whilst this was initially disappointing, it resulted in a number of
well-advanced drug programs reverting to OBT, allowing the company
to seek new partners for those programs. This has generated
significant interest and allowed OBT to re-partner for the
programs, predominantly on better terms given the advances that had
been made with Immunogen.
Rotageek Limited ("Rotageek")
Rotageek provides a workforce
management solution, creating staff schedules using cloud-based
technology, including auto scheduling, to optimise the schedules
based on staffing need, employee wishes and regulatory working time
limits. Rotageek is continuing to
experience good growth with 25% increase in year-on-year ARR as at
September 2024. The company has a strong pipeline of opportunities
and is continuing to consider its strategic options which, with
continuing strong sales, could lead to a sale of the company in or
around 2025.
Riff Raff Entertainment Limited ("Riff
Raff")
Riff Raff is a TV and film
production company founded by Academy Award® nominated actor
Jude Law and his creative partner Ben Jackson. The company has a
film 'First Look' deal with New Republic Pictures (NRP),
contributing to company overheads and funding development on
projects picked up by NRP. The company has also signed a two-year
'First Look' TV deal with Newen for TV projects.
Maven Screen Media Limited ("Maven")
Maven was launched in 2020 by experienced
producers, Academy Award® nominated Celine Rattray and Trudie
Styler. The company focuses on female-focused films, television,
and podcasts often with a social message. In July, the film
Unicorns had a positive UK theatrical release, with Netflix SVOD to
follow during the year. Among other advanced projects, the film
Eleanor the Great, which marks Scarlett Johansson's directorial
debut and is financed by Sony, has finished all the shooting and is
now in post-production.
Censo Biotechnologies Limited ("Axol")
Censo Biotechnologies Ltd (trading
as Axol Bioscience) is a stem cells science company which develops
and manufactures induced pluripotent stem cells (iPSCs) and
provides related laboratory services. In June 2024, Axol raised
£3.6 million through a fully subscribed round in a new senior class
of equity and in October, Axol acquired Phenocell SAS, an iPSC
company specialising in skin and retinal disorders, complementing
Axol's current specialisation on neuroscience, pain and touch and
cardiovascular disorders. During 2024, Axol has been
performing in line with budget, notwithstanding a challenging
period for many other iPSC companies in the market.
Tagomics Limited ("Tagomics")
Tagomics continues to make excellent technical and commercial
progress in the development of its comprehensive disease insight
platform. Tagomics' pioneering platform seamlessly combines 'omics'
technologies, including genomics (detecting mutations), epigenomics
(studying chemical 'switches' on the genome), and fragmentomics
(the analysis of DNA fragmentation patterns in the blood); the
evidence this platform can deliver means that the company has
already attracted significant partners and commercial clients. The
company expects to launch further partnerships over the next 6
months.
Developments since the period end
As mentioned above, the Company
invested an additional £450,000 in a follow-on investment into
Raindog Films Limited which took place in October 2024.
Calculus Capital Limited
Investment Manager
5 December 2024
INVESTMENT PORTFOLIO AS AT 30 SEPTEMBER
2024
-
TOTAL FUND
%
of Net Assets
|
|
Unquoted - loan stock
|
7%
|
Quoted and unquoted - ordinary and
preference shares
|
61%
|
Unquoted - liquidity
funds
|
21%
|
Net current assets
|
11%
|
|
100%
|
|
|
Asset class - % of Portfolio
Company
|
Book
Cost
|
Market Valuation as at 30 September 2024
|
Multiple against book cost as at 30 September
2024
|
Multiple against book cost as 31 March 2024
|
Market Value Movement since 31 March
2024
|
% of
portfolio
|
Qualifying Investments
|
|
|
|
|
|
|
Arctic Shores Limited
|
610
|
610
|
1.00x
|
1.00x
|
0.0%
|
1.7%
|
Arecor Therapeutics plc
|
833
|
274
|
0.33x
|
0.72x
|
-54.1%
|
0.7%
|
Blu Wireless Technologies
Limited
|
833
|
1,042
|
1.25x
|
1.07x
|
17.3%
|
2.8%
|
Brouhaha Entertainment
Limited
|
1,331
|
2,280
|
1.71x
|
1.88x
|
0.0%
|
6.2%
|
C4X Discovery Holdings
Limited
|
598
|
625
|
1.04x
|
0.47x
|
124.1%
|
1.7%
|
Censo Biotechnologies
Limited
|
1,051
|
909
|
0.86x
|
0.86x
|
0.0%
|
2.5%
|
Engaging Works Limited
|
666
|
666
|
1.00x
|
New
|
New
|
1.8%
|
Evoterra Limited
|
1,215
|
256
|
0.21x
|
0.21x
|
0.0%
|
0.7%
|
Fiscaltec Group Limited
|
768
|
1,275
|
1.66x
|
1.58x
|
5.0%
|
3.5%
|
Hinterview Limited
|
800
|
400
|
0.50x
|
0.59x
|
-15.6%
|
1.1%
|
Home Team Content Limited
|
786
|
1,763
|
2.24x
|
2.24x
|
0.0%
|
4.8%
|
Huma Therapeutics Limited (was
eConsult Limited)
|
262
|
264
|
1.01x
|
1.00x
|
-64.8%
|
0.7%
|
Invizius Limited
|
486
|
340
|
0.70x
|
1.14x
|
-36.9%
|
0.9%
|
IPV Limited
|
340
|
409
|
1.20x
|
1.20x
|
0.0%
|
1.1%
|
Laverock Therapeutics
Limited
|
744
|
744
|
1.00x
|
1.00x
|
0.0%
|
2.0%
|
Maven Screen Media Limited
|
798
|
909
|
1.14x
|
1.14x
|
0.0%
|
2.5%
|
Notify Technologies
Limited
|
628
|
731
|
1.16x
|
1.16x
|
0.0%
|
2.0%
|
Open Energy Market Limited
|
200
|
576
|
2.88x
|
2.56x
|
12.5%
|
1.6%
|
Optalitix Limited
|
1,347
|
1,681
|
1.25x
|
1.31x
|
0.00%
|
4.6%
|
Oxford Biotherapeutics
Limited
|
350
|
1,773
|
5.07x
|
5.07x
|
0.0%
|
4.8%
|
Quai Administrations
Limited
|
920
|
1,186
|
1.29x
|
1.27x
|
1.2%
|
3.2%
|
Raindog Films Limited
|
396
|
297
|
0.75x
|
1.00x
|
-25.0%
|
0.8%
|
Riff Raff Entertainment
Limited
|
874
|
1,848
|
2.11x
|
1.94x
|
9.2%
|
5.0%
|
Rota Geek Limited
|
1,530
|
1,930
|
1.26x
|
1.21x
|
4.7%
|
5.3%
|
Scancell Holdings plc
|
378
|
367
|
0.97x
|
0.69x
|
40.0%
|
1.0%
|
Tagomics Limited
|
909
|
909
|
1.00x
|
1.00x
|
0.0%
|
2.5%
|
Thanksbox Limited
|
1,073
|
1,177
|
1.10x
|
1.10x
|
0.0%
|
3.2%
|
Tozaro Limited (was MIP Diagnostics
Limited)
|
982
|
1,078
|
1.10x
|
1.10x
|
0.0%
|
2.9%
|
Wazoku Limited
|
720
|
718
|
1.00x
|
1.61x
|
-38.2%
|
2.0%
|
Wonderhood Limited
|
441
|
723
|
1.64x
|
1.64x
|
0.0%
|
2.0%
|
Other*
|
1,216
|
383
|
0.31x
|
0.44x
|
-49.4%
|
1.0%
|
|
|
|
|
|
|
|
Total Qualifying Investments
|
24,085
|
28,143
|
|
|
|
76.6%
|
|
|
|
|
|
|
|
Other non-Qualifying Investments
|
|
|
|
|
|
|
Aberdeen Sterling Liquidity
Fund
|
2,707
|
2,707
|
1.00x
|
1.00x
|
0.0%
|
7.4%
|
Fidelity Sterling Liquidity
Fund
|
2,883
|
3,171
|
1.10x
|
1.07x
|
2.6%
|
8.6%
|
Goldman Sachs Sterling Liquidity
Fund
|
2,705
|
2,705
|
1.00x
|
1.00x
|
0.0%
|
7.4%
|
Total other non-qualifying investments
|
8,295
|
8,583
|
|
|
|
23.4%
|
Total investments
|
32,380
|
36,726
|
|
|
|
|
Net Current Assets less Creditors due
after one year
|
|
3,201
|
|
|
|
|
Net Non-Current Assets less Creditors
due after one year
|
|
1,362
|
|
|
|
|
Net
Assets
|
|
41,289
|
|
|
|
|
*All individual investee companies
with a market value of less than £0.15 million have been grouped
together as "Other".
PRINCIPAL RISKS
The principal risks facing the
Company remain the same as those detailed on page 32 of the Annual
Report and Accounts for the period ended 31 March 2024.
Brexit is still causing uncertainty
however it remains our view that our portfolio companies are not
experiencing material difficulties as a result of the political
situation.
Regulatory and Compliance risks
remain prevalent as the Company is listed
on The London Stock Exchange and is required to comply with the
listing rules of the Financial Conduct Authority, as well as with
the Companies Act, Accounting Standards and various other
legislations.
The main risks faced by the Company
include, but are not limited to, loss of approval as a venture
capital trust and other regulatory breaches, risks of making and
realising qualifying investments, liquidity/marketability risk,
changes in legislation/taxation, engagement of third-party
advisers, market price risk and credit risk.
GOING CONCERN
After making enquiries, and having
reviewed the portfolio, balance sheet and projected income and
expenditure for the next twelve months, the Directors have a
reasonable expectation that the Company has adequate resources to
continue in operation for the foreseeable future. The Directors
have therefore adopted the going concern basis in preparing these
condensed financial statements.
DIRECTORS' RESPONSIBILITY STATEMENT
The Directors confirm that to the
best of their knowledge the half-yearly financial report, which has
been prepared in accordance with the UK Listing Authority
Disclosure and Transparency Rules ("DTR") and in accordance with
the Financial Reporting Council's Financial Reporting Standard 104:
'Interim Financial Reporting' gives a true and fair view of the
assets, liabilities, financial position and the net return of the
Company as at 30 September 2024.
The Directors confirm that the
Chairman's Update, the Investment Management report, the
disclosures above and notes 10 and 11, include a fair review of the
information required by DTR 4.2.7R, being an indication of
important events that have occurred during the first six months of
the financial year and their impact on the condensed set of
financial statements and a description of the principal risks and
uncertainties for the remaining six months of the financial year,
and DTR 4.2.8R.
The Directors of Calculus VCT plc
are:
Jan Ward
Janine Nicholls
Hemant Mardia
John Glencross
By order of the Board
Jan Ward
Chairman,
5 December 2024
CONDENSED INCOME STATEMENT
FOR
THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER 2024
(UNAUDITED)
|
|
6 Months
Ended
|
6 Months
Ended
|
13 Months
Ended
|
|
|
30 September
2024
|
31 August
2023
|
31 March
2024*
|
|
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
|
|
Return
|
Return
|
Return
|
Return
|
Return
|
Return
|
Return
|
Return
|
Total
|
|
Note
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
|
|
Investment holding losses
|
8
|
-
|
(75)
|
(75)
|
-
|
(370)
|
(370)
|
-
|
(235)
|
(235)
|
(Loss)/gain on disposal of
investments
|
8
|
-
|
(859)
|
(859)
|
-
|
1
|
1
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Income
|
|
401
|
-
|
401
|
296
|
-
|
296
|
726
|
-
|
726
|
|
|
|
|
|
|
|
|
|
|
|
Investment management fee
|
|
(89)
|
(267)
|
(356)
|
(80)
|
(239)
|
(319)
|
(175)
|
(523)
|
(698)
|
Other operating expenses
|
|
(161)
|
-
|
(161)
|
(152)
|
-
|
(152)
|
(328)
|
-
|
(328)
|
|
|
|
|
|
|
|
|
|
|
|
(Loss)/profit on ordinary activities
before taxation
|
|
151
|
(1,201)
|
(1,050)
|
64
|
(608)
|
(544)
|
223
|
(758)
|
(535)
|
|
|
|
|
|
|
|
|
|
|
|
Taxation on ordinary
activities
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
(Loss)/profit for the
period
|
|
151
|
(1,201)
|
(1,050)
|
64
|
(608)
|
(544)
|
223
|
(758)
|
(535)
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted deficit per new
Ordinary share
|
2
|
0.22p
|
(1.74)p
|
(1.52)p
|
0.11p
|
(1.04)p
|
(0.93)p
|
0.37p
|
(1.26)p
|
(0.89)p
|
|
|
|
|
|
|
|
|
|
|
|
*These figures are extracts from
audited accounts. The notes form an
integral part of these Accounts.
The supplementary revenue return and
capital return columns are both prepared in accordance with the
Association of Investment Companies ("AIC") Statement of
Recommended Practice ("SORP"). No operations were acquired or
discontinued during the period. All items in the above statements
derive from continuing operations. There were no recognised gains
or losses other than those passing through the Income Statement.
The notes form an integral part of these condensed financial
statements.
CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR
THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER 2024
(UNAUDITED)
|
|
|
Non-distributable
reserves
|
Distributable
reserves
|
|
|
|
Share
|
|
Capital
|
Capital
|
Capital
|
|
|
|
Share
|
Premium
|
Special
|
Redemption
|
Reserve
|
Reserve
|
Revenue
|
|
|
Capital
|
Account
|
Reserve
|
Reserve
|
Realised
|
Unrealised
|
Reserve
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
For
the 6 months to 30 September 2024
|
|
|
|
|
|
|
|
|
1
April 2024
|
634
|
23,057
|
14,848
|
89
|
(1,918)
|
4,074
|
(1,719)
|
39,065
|
Investment holding losses
|
-
|
-
|
-
|
-
|
-
|
(75)
|
-
|
(75)
|
Loss
on disposal of investments
|
-
|
-
|
-
|
-
|
(859)
|
-
|
-
|
(859)
|
New
share issue
|
96
|
5,752
|
-
|
-
|
-
|
-
|
-
|
5,848
|
Expenses of share issue
|
-
|
(113)
|
-
|
-
|
-
|
-
|
-
|
(113)
|
Share buybacks for cancellation
|
(8)
|
-
|
(472)
|
8
|
-
|
-
|
-
|
(472)
|
Management fee allocated to capital
|
-
|
-
|
-
|
-
|
(267)
|
-
|
-
|
(267)
|
Increase in accrual of IFA Commission
|
-
|
(26)
|
-
|
-
|
-
|
-
|
-
|
(26)
|
Revenue return after tax
|
-
|
-
|
-
|
-
|
-
|
-
|
151
|
151
|
Dividends paid (note 9)
|
-
|
-
|
(1,963)
|
-
|
-
|
-
|
-
|
(1,963)
|
Transfer of previously unrealised loss to
realised
|
-
|
-
|
-
|
-
|
(347)
|
347
|
-
|
-
|
30
September 2024
|
722
|
28,670
|
12,413
|
97
|
(3,391)
|
4,346
|
(1,568)
|
41,289
|
For
the 6 months to 31 August 2023
|
|
|
|
|
|
|
|
|
1 March 2023
|
523
|
14,924
|
17,832
|
69
|
(1,414)
|
4,328
|
(1,942)
|
34,320
|
Investment holding losses
|
-
|
-
|
-
|
-
|
-
|
(370)
|
-
|
(370)
|
Gain on disposal of
investments
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
New share issue
|
97
|
6,235
|
-
|
-
|
-
|
-
|
-
|
6,332
|
Expenses of share issue
|
-
|
(87)
|
-
|
-
|
-
|
-
|
-
|
(87)
|
Share buybacks for
cancellation
|
(3)
|
-
|
(205)
|
3
|
-
|
-
|
-
|
(205)
|
Management fee allocated to
capital
|
-
|
-
|
-
|
-
|
(239)
|
-
|
-
|
(239)
|
Increase in accrual of IFA
Commission
|
-
|
(30)
|
-
|
-
|
-
|
-
|
-
|
(30)
|
Revenue return after tax
|
-
|
-
|
-
|
-
|
-
|
-
|
64
|
64
|
Dividends paid (note 9)
|
-
|
-
|
(1,789)
|
-
|
-
|
-
|
-
|
(1,789)
|
Transfer of previously unrealised
gain to realised
|
-
|
-
|
-
|
-
|
19
|
(19)
|
-
|
-
|
31
August 2023
|
617
|
21,042
|
15,838
|
72
|
(1,633)
|
3,939
|
(1,878)
|
37,997
|
CONDENSED STATEMENT OF CHANGES IN EQUITY
(CONTINUED)
|
|
|
Non-distributable
reserves
|
Distributable
reserves
|
|
|
|
Share
|
|
Capital
|
Capital
|
Capital
|
|
|
|
Share
|
Premium
|
Special
|
Redemption
|
Reserve
|
Reserve
|
Revenue
|
|
|
Capital
|
Account
|
Reserve
|
Reserve
|
Realised
|
Unrealised
|
Reserve
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
For
the 13 months to 31 March 2024*
|
|
|
|
|
|
|
|
|
1 March 2023
|
523
|
14,924
|
17,832
|
69
|
(1,414)
|
4,328
|
(1,942)
|
34,320
|
Investment holding losses
|
-
|
-
|
-
|
-
|
-
|
(235)
|
-
|
(235)
|
New share issue
|
131
|
8,308
|
-
|
-
|
-
|
-
|
-
|
8,439
|
Expenses of share issue
|
-
|
(163)
|
-
|
-
|
-
|
-
|
-
|
(163)
|
Share buybacks for
cancellation
|
(20)
|
-
|
(1,195)
|
20
|
-
|
-
|
-
|
(1,195)
|
Management fee allocated to
capital
|
-
|
-
|
-
|
-
|
(523)
|
-
|
-
|
(523)
|
Decrease in accrual of IFA
commission
|
-
|
(12)
|
-
|
-
|
-
|
-
|
-
|
(12)
|
Revenue return after tax
|
-
|
-
|
-
|
-
|
-
|
-
|
223
|
223
|
Dividends paid
|
-
|
-
|
(1,789)
|
-
|
-
|
-
|
-
|
(1,789)
|
Transfer of previously unrealised
losses to realised
|
-
|
-
|
-
|
-
|
19
|
(19)
|
-
|
-
|
31
March 2024
|
634
|
23,057
|
14,848
|
89
|
(1,918)
|
4,074
|
(1,719)
|
39,065
|
* These figures are extracts from
audited accounts. The notes form an integral part of these
Accounts.
CONDENSED BALANCE SHEET
AS
AT 30 SEPTEMBER 2024
(UNAUDITED)
|
|
30 September
2024
|
31 August
2023
|
31 March
2024*
|
|
Note
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
|
|
|
|
|
Fixed assets
|
|
|
|
|
Investments held at fair value
through profit or loss
|
8
|
36,726
|
35,386
|
37,914
|
Deferred sales awaiting
settlement
|
|
1,234
|
53
|
46
|
Deferred fixed interest awaiting
settlement
|
|
250
|
-
|
-
|
|
|
38,210
|
35,439
|
37,960
|
|
|
|
|
|
Current assets
|
|
|
|
|
Debtors
|
|
314
|
391
|
451
|
Cash at bank and on
deposit
|
|
3,185
|
2,634
|
1,124
|
|
|
3,499
|
3,025
|
1,575
|
|
|
|
|
|
Creditors: amounts falling due within one
year
Creditors
|
|
(298)
|
(321)
|
(357)
|
|
|
|
|
|
Net
current assets
|
|
3,201
|
2,704
|
1,218
|
|
|
|
|
|
Total assets less current liabilities
|
|
41,411
|
38,143
|
39,178
|
|
|
|
|
|
Creditors: amounts falling due after more than one
year
|
|
|
|
|
IFA trail commission
|
|
(122)
|
(146)
|
(113)
|
|
|
|
|
|
Total net assets
|
|
41,289
|
37,997
|
39,065
|
|
|
|
|
|
Capital and reserves
|
|
|
|
|
Called-up share capital
|
6
|
722
|
617
|
634
|
Share premium account
|
|
28,670
|
21,042
|
23,057
|
Special reserve
|
|
12,413
|
15,838
|
14,848
|
Capital redemption
reserve
|
|
97
|
72
|
89
|
Capital reserve -
realised
|
|
(3,391)
|
(1,633)
|
(1,918)
|
Capital reserve -
unrealised
|
|
4,346
|
3,939
|
4,074
|
Revenue reserve
|
|
(1,568)
|
(1,878)
|
(1,719)
|
Total shareholders' funds
|
|
41,289
|
37,997
|
39,065
|
|
|
|
|
|
Net
asset value per new Ordinary share - basic and
diluted
|
4
|
57.20p
|
61.55p
|
61.58p
|
* These figures are extracts from
audited accounts. The notes form an
integral part of these condensed financial
statements.
CONDENSED STATEMENT OF CASH FLOW
FOR
TO THE PERIOD FROM 1 APRIL 2024 TO 30 SEPTEMBER
2024
(UNAUDITED)
|
|
6
Months
|
6
Months
|
13
Months
|
|
|
Ended
|
Ended
|
Ended
|
|
|
30
September
|
31
August
|
31
March
|
|
|
2024
|
2023
|
2024*
|
|
Note
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities
|
|
|
|
|
Investment income
received
|
|
213
|
165
|
395
|
Deposit interest received
|
|
43
|
31
|
52
|
Investment management fees
paid
|
|
(384)
|
(292)
|
(626)
|
Operating expenses
|
|
(172)
|
(190)
|
(362)
|
Net
cash flow from operating activities
|
5
|
(300)
|
(286)
|
(541)
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase of investments
|
|
(1,309)
|
(5,112)
|
(7,815)
|
Sale of investments
|
|
400
|
20
|
460
|
Net
cash flow from investing activities
|
|
(909)
|
(5,092)
|
(7,355)
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
Shares issued
|
|
5,574
|
6,057
|
8,165
|
Expenses of share issues
|
|
(113)
|
(81)
|
(188)
|
IFA trail commission
|
|
(29)
|
(25)
|
(27)
|
Share buybacks for
cancellation
|
|
(473)
|
(205)
|
(1,196)
|
Equity dividend paid
|
9
|
(1,689)
|
(1,514)
|
(1,514)
|
Net
cash flow from financing activities
|
|
3,270
|
4,232
|
5,240
|
Increase/(decrease) in cash and cash
equivalents
|
|
2,061
|
(1,146)
|
(2,656)
|
Opening cash and cash equivalents
|
|
1,124
|
3,780
|
3,780
|
Net
cash increase/(decrease)
|
|
2,061
|
(1,146)
|
(2,656)
|
Closing cash and cash equivalents
|
|
3,185
|
2,634
|
1,124
|
* These figures are extracts from
audited accounts. The notes form an integral part of these
Accounts.
CONDENSED NOTES TO THE ACCOUNTS
1.
Nature of Financial Information
The Company applies FRS 102 and the
Association of Investment Companies ("AIC") SORP for its financial
period ended September 2024 in its Financial Statements. The
financial statements for the six months to 30 September 2024 have
therefore been prepared in accordance with FRS 104 "Interim
Financial Reporting". The condensed financial statements have been
prepared on the same basis as the accounting policies set out in
the statutory accounts for the period ended 31 March
2024.
The financial information contained
in this Half Year Report and Accounts and the comparative figures
for the financial year ended 31 March 2024 are not the Company's
statutory accounts for the financial period as defined in the
Companies Act 2006. The financial information for the periods ended
30 September 2024 and 31 August 2023 have not been
audited.
The Annual Report and Financial
Statements for the financial year ended 31 March 2024 have been
delivered to the Registrar of Companies. The report of the auditors
was: (i) unqualified; (ii) did not include a reference to any
matters which the auditors drew attention by way of emphasis
without qualifying the report; and (iii) did not contain statements
under section 498 (2) and (3) of the Companies Act 2006.
The financial statements have been
prepared on a going concern basis and on the basis that approval as
an investment trust company will continue to be met.
2.
Return per Share (Basic and diluted)
|
6 Months
Ended
|
6 Months
Ended
|
13 Months
Ended
|
|
30 September
2024
|
31 August
2023
|
31 March
2024
|
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
Revenue
|
Capital
|
Total
|
|
pence
|
pence
|
pence
|
pence
|
pence
|
pence
|
pence
|
pence
|
pence
|
|
|
|
|
|
|
|
|
|
|
Return per Ordinary share
|
0.22
|
(1.74)
|
(1.52)
|
0.11
|
(1.04)
|
(0.93)
|
0.37
|
(1.26)
|
(0.89)
|
New
Ordinary shares
Revenue return per Ordinary share is
based on the net revenue gain on ordinary activities after taxation
of £150,730 (31 August 2023: gain £64,012, 31 March 2024: gain
£223,351) and on 69,107,223 (31 August 2023: 58,347,452, 31 March
2024: 60,236,611) Ordinary shares, being the weighted average
number of Ordinary shares in issue during the period.
Capital return per Ordinary share is
based on the net capital loss for the period of £1,200,498 (31
August 2023: loss £608,033, 31 March 2024: loss £758,656) and on
69,107,223 (31 August 2023: 58,347,452, 31 March 2024: 60,236,611)
Ordinary shares, being the weighted average number of Ordinary
shares in issue during the period.
Total return per Ordinary share is
based on the net loss on ordinary activities for the period of
£1,049,768 (31 August 2023: loss £544,021, 31 March 2024: loss
£535,305) and on 69,107,223 (31 August 2023: 58,347,452, 31 March
2024: 60,236,611) Ordinary shares, being the weighted average
number of Ordinary shares in issue during the period.
3.
Taxation on Ordinary Activities
The estimated effective tax rate at
the period end is 0 per cent. This remains unchanged from the prior
year end.
4.
Net Asset Value per Share
|
30
September
|
31
August
|
31
March
|
|
2024
|
2023
|
2024
|
|
Pence
|
Pence
|
Pence
|
|
|
|
|
Net asset value per new Ordinary
share
|
57.20
|
61.55
|
61.58
|
The basic net asset value per new
Ordinary share is based on net assets (including current period
revenue) of £41,288,617 (31 August 2023: £37,997,043, 31 March
2024: £39,064,804) and on 72,181,123 (31 August 2023: 61,733,566,
31 March 2024: 63,441,389) Ordinary shares, being the number of new
Ordinary shares in issue at the period end.
5.
Reconciliation of Net Profit before Tax to Cash
Flow from Operating Activities
|
30
September
|
31
August
|
31
March
|
|
2024
|
2023
|
2024
|
|
£'000
|
£'000
|
£'000
|
|
|
|
|
Loss on ordinary activities before
tax
|
(1,050)
|
(544)
|
(535)
|
Loss on investments
|
934
|
369
|
235
|
Increase in debtors
|
(106)
|
(97)
|
(227)
|
(Decrease)/increase in
creditors
|
(46)
|
(14)
|
39
|
Non cash movement
|
(32)
|
-
|
(53)
|
|
|
|
|
Cash flow from operating activities
|
(300)
|
(286)
|
(541)
|
6.
Called up share capital
|
|
30
September
|
|
|
2024
|
|
Number
|
£'000
|
|
|
|
Ordinary shares of 1p
each
|
72,181,123
|
722
|
In April 2024 the Company issued
5,257,265 Ordinary shares for a total consideration of £3,176,829.
Also in April 2024, the Company bought back for cancellation
833,854 Ordinary shares for a total consideration of £472,373. In
July 2024, 2,992,248 Ordinary shares were issued for a total
consideration of £1,877.375. In August 2024, 463,382 Ordinary
shares were issued under the Dividend Re-Investment Scheme. Also in
August 2024, 860,693 Ordinary shares were issued for a total
consideration of £519,788.
Following the issues and
cancellation noted above there were 72,181,123 Ordinary shares in
issue as at 30 September 2024.
7.
Contingent assets and contingent liabilities
There were no contingent assets or
contingent liabilities in existence at 30 September 2024 (31 August
2023: £nil, 31 March 2024: £nil).
8.
Fair Value Hierarchy
Investments held at fair value
through profit or loss are valued in accordance with IPEV
guidelines.
The valuation method used will be
the most appropriate valuation methodology for an investment within
its market, with regard to the financial health of the investment
and the IPEV guidelines. As required by the Standard, an analysis
of financial assets and liabilities, which identifies the risk of
the Company's holding of such items is provided. The Standard
requires an analysis of investments carried at fair value based on
the reliability and significance of the information used to measure
their fair value.
In order to provide further
information on the valuation techniques used to measure assets
carried at fair value, we have categorised the measurement basis
into a "fair value hierarchy" as follows:
- Quoted market
prices in active markets - "Level 1"
Inputs to Level 1 fair values are
quoted prices for identical asset in an active market. Quoted in an
active market in this context means quoted prices are readily and
regularly available and those prices represent actual and regularly
occurring market transactions on an arm's length basis. The quoted
price is usually the current bid price. The Company's investments
in AIM quoted equities and money market funds are classified within
this category.
- Valued using
models with significant observable market inputs - "Level
2"
Inputs to Level 2 fair values are
inputs other than quoted prices included within Level 1 that are
observable for the asset, either directly or indirectly.
- Valued using
models with significant unobservable market inputs - "Level
3"
Inputs to Level 3 fair values are
unobservable inputs for the asset. Unobservable inputs may have
been used to measure fair value to the extent that observable
inputs are not available, thereby allowing for situations in which
there is little, if any, market activity for the asset at the
measurement date (or market information for the inputs to any
valuation models). As such, unobservable inputs reflect the
assumptions the Company considers that market participants would
use in pricing the asset. The Company's unquoted equities and loan
stock are classified within this category. Unquoted investments are
valued in accordance with the IPEV guidelines.
|
Level 1
|
Level 2
|
Level 3
|
Total
|
Investments
|
£'000
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
|
|
|
|
|
Opening book cost
|
11,106
|
-
|
22,734
|
33,840
|
Opening unrealised
appreciation/(depreciation)
|
(1,079)
|
-
|
5,153
|
4,074
|
Opening fair value
|
10,027
|
-
|
27,887
|
37,914
|
|
|
|
|
|
Movements in the period:
|
|
|
|
|
Purchase at cost
|
-
|
-
|
1,342
|
1,342
|
Sales - proceeds
|
-
|
-
|
(1,596)
|
(1,596)
|
Sales - realised losses on
sales
|
-
|
-
|
(859)
|
(859)
|
Prior year unrealised losses
realised during the period
|
(2)
|
-
|
(345)
|
(347)
|
Transfer from Level 1 to Level
3
|
(1,098)
|
-
|
1,098
|
-
|
Unrealised investment
gains/(losses)
|
361
|
-
|
(89)
|
272
|
Closing fair value
|
9,288
|
-
|
27,438
|
36,726
|
|
|
|
|
|
Closing book cost
|
10,006
|
-
|
22,374
|
32,380
|
Closing unrealised
appreciation/(depreciation)
|
(718)
|
-
|
5,064
|
4,346
|
Closing fair value
|
9,288
|
-
|
27,438
|
36,726
|
|
|
|
|
|
9.
Dividends
For the period ended 31 March 2024,
the Company declared a final dividend of 2.77p per share on
70,857,048 eligible shares amounting to £1,962,732. The dividend
was paid on 29 August 2024.
Of the total number of eligible
shares due this dividend, 60,975,166 were paid in cash, totalling
£1,689,005. The remaining shares elected to participate in the
Dividend Re-Investment Scheme. As a result, a further 463,382
Ordinary Shares were issued at a value of £273,727.
10.
Transactions with Related Parties
John Glencross, a Director of the
Company, is considered to be a related party due to his position as
Chief Executive and a director of Calculus Capital Limited, the
Company's Investment Manager.
Calculus Capital Limited receives an
investment manager's fee from the Company. For the 6 months to 30
September 2024, Calculus Capital Limited earned £355,572 of
Management Fees. (31 August 2023: £319,340; 31 March 2024:
£697,848). Calculus Capital Limited also earned a company
secretarial fee of £9,000 (31 August 2023: £9,000; 31 March 2024: £19,500).
At 30 September 2024, £189,632 was due to Calculus Capital Limited (31 August
2023: £172,871; 31 March 2024: £219,178) in
relation to unpaid investment manager's and company secretarial
fees.
Calculus Capital Limited took on the
expenses cap on 15 December 2015. In the 6 months to 30 September
2024, Calculus Capital Limited did not contribute towards the
expenses. (31 March 2024: contributed £nil).
11.
Transactions with Investment Managers
John Glencross, a Director of the
Company, is Chief Executive and a director of Calculus Capital
Limited, the Company's Manager. He does not receive any
remuneration from the Company. He is a director of Brouhaha
Entertainment Limited, Home Team Content Limited, Maven Screen
Media Limited, Raindog Films Limited, Riff Raff Entertainment
Limited and Wonderhood Studios Limited.
Calculus Capital receives fees from
certain portfolio companies. The aggregate net amounts received by
Calculus Capital Limited for any monitoring, provision of a
director and arrangement fees, as appropriate, from the investee
companies was £444,000 for the period to 30 September 2024
(£396,000 to 31 August 2023; £1,099,000 to 31 March
2024).
12.
Post balance sheet events
Since the period end, the Company has
made follow on investments of £450,000 in Raindog Films
Limited
The Company also bought back and
cancelled 517,241 shares in October 2024
for an aggregate consideration of £290,276.
COMPANY INFORMATION
Directors
|
Fund Administrator
|
Jan Ward
Janine Nicholls
|
Waystone Administration Solutions
(UK) Limited
|
John Glencross
|
Broadwalk House
|
Hemant Mardia
|
Southernhay West
|
|
Exeter EX1 1TS
|
|
|
|
|
Registered Office
|
Auditors
|
12 Conduit Street
|
Moore Kingston Smith
|
London
|
6th Floor, 9 Appold
Street
|
W1S 2XH
|
London EC2A 2AP
|
Telephone: 020 7493 4940
|
|
|
Broker
|
Company Number
|
Singer Capital Markets
|
07142153
|
1 Bartholomew Lane
|
|
London EC2N 2AX
|
|
|
Venture Capital Investments Manager
|
Registrars
|
And
Company Secretary
|
The City Partnership (UK)
Limited
|
12 Conduit Street
|
The Mending Rooms
|
London
|
Park Valley Mills
|
W1S 2XH
|
Meltham Road
|
Telephone: 020 7493 4940
|
Huddersfield
|
Website: www.calculuscapital.com
|
HD4 7BH
|
|
|
|
|
Sponsor
Beaumont Cornish Limited
10th Floor, 30 Crown Pl, Hackney
London EC2M 2SJ
|
|
|
|
|
|
|
|
|
|
Legal Entity Identifier:
2138005SMDWLMMNPVA90
Printed copies of the Calculus VCT
plc Half Yearly Report for the six months ended 30 September
2024 have not been posted to shareholders. However, a copy can be
found on the following website: https://calculuscapital.com/products/calculus-vct/investor-information/
For further information, please
contact:
Calculus Capital Limited
Telephone: 020 7493 4940
Neither the contents of the
Company's website nor the contents of any website accessible from
hyperlinks on this announcement (or any other website) are
incorporated into, or form part of, this announcement.
END